Skip to main content

1 Result(s)

within Ayaka Isogai Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study

    Trastuzumab deruxtecan (T-DXd) can improve the prognosis of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, data on treatment recommendations aft...

    Ayaka Isogai, Kazuki Nozawa, Akira Nakakami… in Breast Cancer Research and Treatment (2024)